Adaptimmune Therapeutics PLC Form 3 November 28, 2016

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

À Kerr Giles Francis Bertram

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

11/01/2016

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]

> 4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

THE OLD VICARAGE, **LOWER** GREEN,, TOWERSEY,

**THAME** 

(Street)

(Check all applicable)

10% Owner \_X\_ Director Officer Other (give title below) (specify below)

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

# OXFORDSHIRE, X0Â OX9 3QW

(City) (State)

1. Title of Security (Instr. 4)

(Zip)

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership

Table I - Non-Derivative Securities Beneficially Owned

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Form: Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

4. 5. Ownership Conversion or Exercise Form of Price of Derivative

Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Security:

1

## Edgar Filing: Adaptimmune Therapeutics PLC - Form 3

Date Expiration Title Exercisable Date

Amount or Security Number of

Shares

Direct (D) or Indirect (I)

(Instr. 5)

**Reporting Owners** 

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Â

Â

Â

Kerr Giles Francis Bertram

THE OLD VICARAGE, LOWER GREEN,

TOWERSEY, THAME

OXFORDSHIRE, X0Â OX9 3QW

**Signatures** 

/s/ Giles Francis 11/28/2016 Bertram Kerr

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

No securities are beneficially owned

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

ÂX

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2